Pharmaceuticals

Minimal Residual Disease Testing Market to Reach $2.91 Billion by 2029, Growing at a CAGR of 12.8%

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Minimal Residual Disease Testing Industry In 2025?

The minimal residual disease testing market has experienced substantial growth in recent years. Its value is expected to increase from $1.59 billion in 2024 to $1.8 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.9%. The expansion observed historically stems from advancements in cancer research, the necessity for treatment monitoring, compelling clinical evidence, regulatory backing, and improvements in patient outcomes.

The minimal residual disease testing market is anticipated to experience swift expansion over the coming years. It is projected to reach $2.91 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.8%. This projected growth during the forecast period stems from factors such as increasing cancer incidence, therapeutic advancements, precision medicine trends, a shift toward early detection, and healthcare system integration. Noteworthy trends anticipated in this period encompass the integration of liquid biopsy approaches, a strong focus on the early detection of relapse, the expansion of MRD testing in clinical trials, its growing adoption in pediatric oncology, and increased collaborations for research and development.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp

Which Factors And Drivers Are Influencing The Minimal Residual Disease Testing Market In 2025?

The rising occurrence of cancer is anticipated to drive expansion in the minimal residual disease testing market moving ahead. Cancer is defined as a state where some of the body’s cells proliferate uncontrollably and disseminate to various parts of the body. Minimal residual disease testing, a highly sensitive technique for identifying cancer cells in the human body, is the primary means of detecting cancer stages. This enables cancer patients to avert the illness early, thereby stimulating the minimal residual disease testing market. As an illustration, for 2022, reports from the American Cancer Society Inc., a US-based nonprofit organization, indicated that around 1.9 million new cases of cancer were expected to be diagnosed, resulting in an estimated 609,360 cancer-related deaths in the United States. Consequently, the expanding incidence of cancer is propelling the minimal residual disease testing market’s growth.

How Is The Minimal Residual Disease Testing Market Classified Into Different Segments?

The minimal residual disease testing market covered in this report is segmented –

1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test

2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies

3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application

4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users

Subsegments:

1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR

2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)

3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry

What Are The Major Trends Driving The Growth Of The Minimal Residual Disease Testing Market?

Product innovations are a significant trend gaining traction in the minimal residual disease testing market. Major companies active in the minimal residual disease testing market are developing novel products to maintain their industry standing. For instance, in 2022, Twist Bioscience, a US-based synthetic biology and genomics company, launched the Twist MRD Panel to advance research and development for minimal residual disease (MRD) detection in cancer screening. The Twist MRD Panel is a customizable gene panel capable of identifying very low concentrations of residual cancer cells in a patient’s blood. Designed for high flexibility and customization, the Twist MRD Panel seamlessly integrates into typical next-generation sequencing (NGS) workflows, allowing for the detection of minimum residual disease (MRD) in just five days.

Who Are The Primary Competitors In The Global Minimal Residual Disease Testing Market?

Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-testing-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Minimal Residual Disease Testing Market?

North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Minimal Residual Disease Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9970&type=smp

Browse Through More Reports Similar to the Global Minimal Residual Disease Testing Market 2025, By The Business Research Company

Healthcare Analytical Testing Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/healthcare-analytical-testing-services-global-market-report

Automotive Testing Inspection And Certification Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/automotive-testing-inspection-and-certification-global-market-report

Cold Plasma Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cold-plasma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795